Molecular characterization and age of cases with gene fusions in AML and MDS
| . | Cases with novel fusions only . | Cases with known fusions . | Cases with no detected fusion . |
|---|---|---|---|
| AML | |||
| TP53 mutations | 67* | 1 | 9 |
| Complex karyotype | 71* | 1 | 9 |
| FLT3-ITD | 0 | 13 | 24 |
| NPM1 mutations | 8 | 0 | 35 |
| RUNX1 mutations | 8 | 2 | 12 |
| CEBPA mutations (biallelic) | 0 | 0 | 5 |
| Median age, y | 72 | 54* | 70 |
| MDS | |||
| TP53 mutations | 26* | 0 | 6 |
| Complex karyotype | 21* | 0 | 1 |
| Median age, y | 67 | 46 | 73 |
| . | Cases with novel fusions only . | Cases with known fusions . | Cases with no detected fusion . |
|---|---|---|---|
| AML | |||
| TP53 mutations | 67* | 1 | 9 |
| Complex karyotype | 71* | 1 | 9 |
| FLT3-ITD | 0 | 13 | 24 |
| NPM1 mutations | 8 | 0 | 35 |
| RUNX1 mutations | 8 | 2 | 12 |
| CEBPA mutations (biallelic) | 0 | 0 | 5 |
| Median age, y | 72 | 54* | 70 |
| MDS | |||
| TP53 mutations | 26* | 0 | 6 |
| Complex karyotype | 21* | 0 | 1 |
| Median age, y | 67 | 46 | 73 |
Data are percentages unless otherwise noted.
Significant differences.